The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of ZELTIQ Aesthetics, Inc.

Levi & Korsinsky is investigating potential claims of breaches of fiduciary duty against the board of directors of ZELTIQ Aesthetics, Inc. (“ZELTIQ” or the “Company”) (Nasdaq: ZLTQ). The investigation concerns whether the Company made materially false and misleading statements and failed to disclose materially adverse information concerning delayed sales and increased competition from competitors in the Company’s LipoSonix business.

For more information, click here:

On March 6, 2012, ZELTIQ announced its fourth quarter 2011 sales and profits were far below analyst estimates. ZELTIQ also lowered its guidance for 2012, predicting sales in the range of $90 to $94 million, far below analyst expectations of $114 million.

If you own ZELTIQ stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value